Renaissance Technologies
DYN icon

Renaissance Technologies’s Dyne Therapeutics DYN Stock Holding History

Renaissance Technologies’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.01M Sell
360,572
-173,028
-32% -$3.22M 0.01% 1178
2026
Q1 		$9.67M Buy
533,600
+62,955
+13% +$1.09M 0.02% 985
2025
Q4 		$9.21M Buy
470,645
+125,145
+36% +$2.37M 0.01% 958
2025
Q3 		$4.37M Buy
+345,500
New +$3.94M 0.01% 1580
2024
Q3 		– Sell
-126,000
Closed -$4.45M – 3609
2024
Q2 		$4.45M Buy
+126,000
New +$3.66M 0.01% 1378
2023
Q2 		– Sell
-73,300
Closed -$844K – 4005
2023
Q1 		$844K Sell
73,300
-34,400
-32% -$447K ﹤0.01% 2584
2022
Q4 		$1.25M Buy
107,700
+2,800
+3% +$32.4K ﹤0.01% 2397
2022
Q3 		$1.33M Buy
104,900
+13,700
+15% +$157K ﹤0.01% 2315
2022
Q2 		$627K Buy
91,200
+48,500
+114% +$334K ﹤0.01% 3017
2022
Q1 		$412K Sell
42,700
-25,800
-38% -$220K ﹤0.01% 3302
2021
Q4 		$814K Sell
68,500
-72,000
-51% -$1.01M ﹤0.01% 2798
2021
Q3 		$2.28M Buy
+140,500
New +$2.49M ﹤0.01% 1986

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Renaissance Technologies's DYN Position: Q2 2026 in Review

Renaissance Technologies reduced its Dyne Therapeutics (DYN) stake by 32% in Q2 2026, selling an estimated $3.22M and leaving 360,572 shares worth $8.01M. The position accounts for 0.01% of the portfolio, ranked #1178.

Renaissance Technologies first reported a position in DYN in Q3 2021 and has held it in 12 quarters since. The position peaked at $9.67M in Q1 2026. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Renaissance Technologies held 360,572 shares of Dyne Therapeutics worth $8.01M as of Q2 2026.
  • Renaissance Technologies sold 173,028 Dyne Therapeutics shares in Q2 2026, an estimated $3.22M.
  • Dyne Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1178 holding.
  • Renaissance Technologies first reported a position in Dyne Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Renaissance Technologies's Dyne Therapeutics position peaked at $9.67M in Q1 2026.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.